within Pharmacolibrary.Drugs.ATC.L;

model L04AB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.05 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,
    adminCount     = 1,
    Vd             = 0.00015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Afelimomab is a recombinant monoclonal antibody fragment (F(ab')2) directed against tumor necrosis factor-alpha (TNF-α). It was developed for the adjunctive treatment of sepsis and septic shock by neutralizing TNF-α-mediated inflammatory responses. Afelimomab is not currently approved or in therapeutic use, as clinical development was discontinued.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult subjects, based on typical monoclonal antibody fragment (F(ab')2) pharmaco-kinetics and publicly available summary data; no peer-reviewed publication with detailed human PK model available.</p><h4>References</h4><ol><li><p>Gallagher, J, et al., &amp; Velagapudi, R (2001). A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome. <i>Intensive care medicine</i> 27(7) 1169–1178. DOI:<a href=&quot;https://doi.org/10.1007/s001340100973&quot;>10.1007/s001340100973</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11534565/&quot;>https://pubmed.ncbi.nlm.nih.gov/11534565</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AB03;
